The DOI matches its Crossref record.
Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease
Abstract
We studied the accumulation of neurofibrillary tangles (NFTs) and senile plaques (SPs) in 10 Alzheimer's disease patients who had been examined during life. We counted NFTs and SPs in 13 cytoarchitectural regions representing limbic, primary sensory, and association cortices, and in subcortical neurotransmitter-specific areas. The degree of neuropathologic change was compared with the severity of dementia, as assessed by the Blessed Dementia Scale and duration of illness. We found that (1) the severity of dementia was positively related to the number of NFTs in neocortex, but not to the degree of SP deposition; (2) NFTs accumulate in a consistent pattern reflecting hierarchic vulnerability of individual cytoarchitectural fields; (3) NFTs appeared in the entorhinal cortex, CA1/subiculum field of the hippocampal formation, and the amygdala early in the disease process; and (4) the degree of SP deposition was also related to a hierarchic vulnerability of certain brain areas to accumulate SPs, but the pattern of SP distribution was different from that of NFT.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Studies have shown that their number and location correlates with neuronal loss, disease severity and clinical course [65, 66].”
From The neuropathological diagnosis of Alzheimer's disease (2019) · cites this paper as [66]
In the citing paper
“Neurofibrillary tangles and quantitative neuronal loss, but not amyloid plaques, have been found to correlate with disease severity and dementia duration [21–23].”
From Clinical trials of new drugs for Alzheimer disease (2020) · cites this paper as [22]
In the citing paper
“to correlate with measures of cognitive decline (Arriagada et al., 1992) in humans.”
From Network analysis identifies strain-dependent response to tau and tau seeding-associated genes (2023) · cites this paper as Arriagada et al., 1992
In the citing paper
“In AD patients, the clinical severity of dementia strongly correlates with the load of pathological tau aggregates. 3 , 4”
From Senescence, brain inflammation, and oligomeric tau drive cognitive decline in Alzheimer's disease: Evidence from clinical and preclinical studies (2024) · cites this paper as [3]
In the citing paper
“Correlations between NFT density and clinical symptoms, such as a cognitive decline in AD, have been demonstrated [11, 12].”
From Tau and neuroinflammation in Alzheimer’s disease: interplay mechanisms and clinical translation (2023) · cites this paper as [11]
In the citing paper
“Increasing evidence demonstrates that the cognitive dysfunction and severity of the disease are more related to tau pathology [11–14].”
From Tau and neuroinflammation in Alzheimer’s disease: interplay mechanisms and clinical translation (2023) · cites this paper as [11]
In the citing paper
“Tau has received increasing attention as a potential therapeutic target, since evidence indicates that tau pathology is more associated with cognitive dysfunction.”
From Tau and neuroinflammation in Alzheimer’s disease: interplay mechanisms and clinical translation (2023) · cites this paper as [11]
In the citing paper
“NFTs and quantitative neuronal loss may be more closely correlated with disease severity and dementia progression than the amyloid plaque burden [20–22].”
From Clinical trials of new drugs for Alzheimer disease: a 2020–2023 update (2023) · cites this paper as [21]
In the citing paper
“the best pathological correlate for clinical symptoms to date is the extent of NFT formation (Arriagada et al., 1992; Brier et al., 2016; Giannakopoulos et al., 2003)”
From Selective Neuronal Vulnerability in Alzheimer’s Disease: A Network-Based Analysis (2020) · cites this paper as Arriagada et al., 1992
In the citing paper
“a large number of studies have arrived at a common finding, namely, there is a strong link between neocortical NFTs and cognitive decline (Tomlinson et al., 1970; Duyckaerts et al., 1990, 1997, 1998; Mckee et al., 1991; Arriagada et al., 1992;”
From Using mice to model Alzheimer's dementia: an overview of the clinical disease and the preclinical behavioral changes in 10 mouse models (2014) · cites this paper as Arriagada et al., 1992
Citations
Cites
Still being checked.
Cited by
Sorted by citations
Items 501–600 of 1,025
Detection of Alzheimer Pathology In Vivo Using Both 11C-PIB and 18F-FDDNP PET
Tolboom, N., Yaqub, M. M., van der Flier, W. M., Boellaard, R., Luurtsema, G., Windhorst, A. D., Barkhof, F., Scheltens, P., Lammertsma, A. A., & van Berckel, B. N. M. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.056499 · Cited by 119
Cellular senescence in aging and age-related diseases: Implications for neurodegenerative diseases
(2020) · International Review of Neurobiology · doi:10.1016/bs.irn.2020.03.019 · Cited by 114
New perspectives on the role of tau in Alzheimer's disease. Implications for therapy
Medina, M., & Ávila, J. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.01.013 · Cited by 123
Excitatory-inhibitory imbalance in Alzheimer's disease and therapeutic significance
Varela, E. V., Etter, G., & Williams, S. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.04.010 · Cited by 122
Lewczuk, P., Esselmann, H., Bibl, M., Beck, G., Maler, J. M., Otto, M., Kornhuber, J., & Wiltfang, J. (2004) · Journal of Molecular Neuroscience · doi:10.1385/jmn:23:1-2:115 · Cited by 117
Hof, P. R. (1992) · Archives of Neurology · doi:10.1001/archneur.1992.00530330070019 · Cited by 118
Cell Death and NeurodegenerationPreprint
Andreone, B. J., Larhammar, M., & Lewcock, J. W. (2019) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a036434 · Cited by 124
Gaikwad, S., Senapati, S., Haque, M. A., & Kayed, R. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13490 · Cited by 117
Immunotherapy Targeting Pathological Tau Protein in Alzheimer's Disease and Related Tauopathies
Sigurdsson, E. M. (2008) · Journal of Alzheimer's Disease · doi:10.3233/jad-2008-15202 · Cited by 116
Predicting future rates of tau accumulation on PET
Jack, C. R., Wiste, H. J., Weigand, S. D., Therneau, T. M., Lowe, V. J., Knopman, D. S., Botha, H., Graff-Radford, J., Jones, D. T., Ferman, T. J., et al. (2020) · Brain · doi:10.1093/brain/awaa248 · Cited by 117
Neuropathogenesis-on-chips for neurodegenerative diseases
Amartumur, S., Nguyen, H. M., Huynh, T., Kim, T. S., Woo, R., Oh, E., Kim, K. K., Lee, L. P., & Heo, C. (2024) · Nature Communications · doi:10.1038/s41467-024-46554-8 · Cited by 131
Fifre, A., Sponne, I., Koziel, V., Kriem, B., Yen, F. T., Bihain, B. E., Olivier, J. L., Oster, T., & Pillot, T. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m507378200 · Cited by 124
Amyloid‐β associated volume loss occurs only in the presence of phospho‐tau
Desikan, R. S., McEvoy, L. K., Thompson, W. K., Holland, D., Roddey, J. C., Blennow, K., Aisen, P. S. S., Brewer, J. B., Hyman, B. T., & Dale, A. M. (2011) · Annals of Neurology · doi:10.1002/ana.22509 · Cited by 118
Self-citationNeuropsychological features of early Alzheimer's disease: preclinical and clinical stages
Almkvist, O. (1996) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1996.tb05874.x · Cited by 122
Detection of entorhinal layer II using Tesla magnetic resonance imaging
Augustinack, J. C., van der Kouwe, A. J. W., Blackwell, M. L., Salat, D. H., Wiggins, C. J., Frosch, M. P., Wiggins, G. C., Potthast, A., Wald, L. L., & Fischl, B. R. (2005) · Annals of Neurology · doi:10.1002/ana.20426 · Cited by 117
Wiltfang, J., Lewczuk, P., Riederer, P. F., Grünblatt, E., Hock, C., Scheltens, P., Hampel, H. J., Vanderstichele, H., Iqbal, K., Galasko, D. R., et al. (2005) · The World Journal of Biological Psychiatry · doi:10.1080/15622970510029786 · Cited by 120
Welikovitch, L. A., Do Carmo, S., Maglóczky, Z., Malcolm, J. C., Lőke, J., Klein, W. L., Freund, T., & Cuello, A. C. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1914593117 · Cited by 116
The keystone of Alzheimer pathogenesis might be sought in Aβ physiology
Puzzo, D., Gulisano, W., Arancio, O., & Palmeri, A. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.08.039 · Cited by 116
Hamilton, L. K., Aumont, A., Julien, C., Vadnais, A., Calon, F., & Fernandes, K. J. L. (2010) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2010.07379.x · Cited by 127
Synaptic tau: A pathological or physiological phenomenon?
Robbins, M., Clayton, E. L., & Schierle, G. S. K. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01246-y · Cited by 128
Götz, J., Ittner, L. M., & Kins, S. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03955.x · Cited by 119
Casein kinase 1 delta mRNA is upregulated in Alzheimer disease brain
Yasojima, K., Kuret, J., DeMaggio, A. J., McGeer, E. G., & McGeer, P. L. (2000) · Brain Research · doi:10.1016/s0006-8993(00)02200-9 · Cited by 120
Alvarez, G., Muñoz-Montaño, J. R., Satrústegui, J., Ávila, J., Bogónez, E., & Díaz‐Nido, J. (2002) · Bipolar Disorders · doi:10.1034/j.1399-5618.2002.01150.x · Cited by 116
Nakajima, A., Aoyama, Y., Nguyen, T.-T. L., Shin, E.-J., Kim, H.-C., Yamada, S., Nakai, T., Nagai, T., Yokosuka, A., Mimaki, Y., et al. (2013) · Behavioural Brain Research · doi:10.1016/j.bbr.2013.05.025 · Cited by 115
Nelson, P. T., Abner, E. L., Schmitt, F. A., Kryscio, R. J., Jicha, G. A., Santacruz, K., Smith, C. D., Patel, E., & Markesbery, W. R. (2009) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3181aacbe9 · Cited by 115
Tau as a therapeutic target in neurodegenerative disease
Himmelstein, D. S., Ward, S., Lancia, J. K., Patterson, K. R., & Binder, L. I. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.07.001 · Cited by 122
Regional brain hypometabolism is unrelated to regional amyloid plaque burden
Altmann, A., Ng, B., Landau, S. M., Jagust, W. J., & Greicius, M. D. (2015) · Brain · doi:10.1093/brain/awv278 · Cited by 117
Aggregation and disaggregation of senile plaques in Alzheimer disease
Cruz, L., Urbanc, B., Buldyrev, S. V., Christie, R. H., Gómez‐Isla, T., Havlin, S., McNamara, M. J., Stanley, E., & Hyman, B. T. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.14.7612 · Cited by 115
Self-citationBancher, C., & Jellinger, K. A. (1994) · Acta Neuropathologica · doi:10.1007/bf00296494 · Cited by 115
The neuritic plaque facilitates pathological conversion of tau in an Alzheimer’s disease mouse model
Li, T., Braunstein, K. E., Zhang, J., Lau, A., Sibener, L., Deeble, C., & Wong, P. C. (2016) · Nature Communications · doi:10.1038/ncomms12082 · Cited by 114
3‐O‐Sulfation of Heparan Sulfate Enhances Tau Interaction and Cellular Uptake
Zhao, J., Zhu, Y., Song, X., Xiao, Y., Su, G., Liu, X., Wang, Z., Xu, Y., Liu, J., Eliezer, D., et al. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201913029 · Cited by 113
Inflammatory pathogenesis in Alzheimer's disease: biological mechanisms and cognitive sequeli
Gahtan, E., & Overmier, J. B. (1999) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(98)00058-x · Cited by 114
Laurent Younes, B., Albert, M., & Miller, M. I. (2014) · NeuroImage Clinical · doi:10.1016/j.nicl.2014.04.009 · Cited by 111
Togo, T., & Dickson, D. W. (2002) · Acta Neuropathologica · doi:10.1007/s00401-002-0569-x · Cited by 116
The role of caspases in Alzheimer’s disease; potential novel therapeutic opportunities
Rohn, T. T. (2010) · APOPTOSIS · doi:10.1007/s10495-010-0463-2 · Cited by 112
Nitsch, R. M., Rebeck, G. W., Deng, M., Richardson, U. I., Tennis, M., Schenk, D. B., Vigo‐Pelfrey, C., Lieberburg, I., Wurtman, R. J., Hyman, B. T., et al. (1995) · Annals of Neurology · doi:10.1002/ana.410370414 · Cited by 113
Self-citationGeorge, R. C., Lew, J., & Graves, D. J. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-122113 · Cited by 114
Therapeutic strategies for the treatment of tauopathies: Hopes and challenges
Khanna, M. R., Kovalevich, J., Lee, V. M. ‐., Trojanowski, J. Q., & Brunden, K. R. (2016) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2016.06.006 · Cited by 116
CryoET of β-amyloid and tau within postmortem Alzheimer’s disease brain
Gilbert, M. A. G., Fatima, N., Jenkins, J., O’Sullivan, T. J., Schertel, A., Halfon, Y., Wilkinson, M., Morrema, T. H. J., Geibel, M., Read, R. J., et al. (2024) · Nature · doi:10.1038/s41586-024-07680-x · Cited by 123
Distinct Therapeutic Mechanisms of Tau Antibodies
Funk, K. E., Mirbaha, H., Jiang, H., Holtzman, D. M., & Diamond, M. I. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.657924 · Cited by 111
Correlation of In Vivo [18F]Flortaucipir With Postmortem Alzheimer Disease Tau Pathology
Smith, R., Wibom, M., Pawlik, D., Englund, E., & Hansson, O. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2018.3692 · Cited by 111
Hook, G., HOOK, V. Y. H., & Kindy, M. S. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-110101 · Cited by 114
Synaptic Amyloid-β Oligomers Precede p-Tau and Differentiate High Pathology Control Cases
Bilousova, T., Miller, C. A., Poon, W. W., Vinters, H. V., Corrada, M., Kawas, C., Hayden, E. Y., Teplow, D. B., Glabe, C., Albay, R., et al. (2016) · The American Journal of Pathology · doi:10.1016/j.ajpath.2015.09.018 · Cited by 115
Nrf2/ARE Pathway Modulation by Dietary Energy Regulation in Neurological Disorders
Vasconcelos, A. R., dos Santos, N. B., Scavone, C., & Munhoz, C. D. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00033 · Cited by 113
Spreading of tau pathology in A lzheimer's disease by cell‐to‐cell transmission
Mohamed, N., Herrou, T., Plouffe, V., Piperno, N., & Leclerc, N. M. (2013) · European Journal of Neuroscience · doi:10.1111/ejn.12229 · Cited by 116
Are Tangles as Toxic as They Look?
Spires-Jones, T. L., Kopeikina, K. J., Koffie, R. M., de Calignon, A., & Hyman, B. T. (2011) · Journal of Molecular Neuroscience · doi:10.1007/s12031-011-9566-7 · Cited by 104
Self-citationPET Quantification of Tau Pathology in Human Brain with 11C-PBB3
Kimura, Y., Ichise, M., Ito, H., Shimada, H., Ikoma, Y., Seki, C., Takano, H., Kitamura, S., Shinotoh, H., Kawamura, K., et al. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.160127 · Cited by 111
Gour, N., Ranjeva, J., Ceccaldi, M. P., Sylviane Confort-gouny, A., Barbeau, E. J., Soulier, E., Guye, M., Didic, M., & Félician, O. (2011) · NeuroImage · doi:10.1016/j.neuroimage.2011.05.090 · Cited by 107
Systemic and CNS Inflammation Crosstalk: Implications for Alzheimer’s Disease
Paouri, E., & Georgopoulos, S. (2019) · Current Alzheimer Research · doi:10.2174/1567205016666190321154618 · Cited by 109
Kantarci, K., Smith, G. E., Ivnik, R. J., Petersen, R. C., Boeve, B. F., Knopman, D. S., Tangalos, E. G., & Jack, C. R. (2002) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617702870084 · Cited by 108
Prevalence, incidence and duration of Braak's stages in the general population: can we know?
Duyckaerts, C., & Hauw, J.-J. (1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00047-x · Cited by 109
Alzheimer disease therapeutics: Focus on the disease and not just plaques and tangles
Iqbal, K., Liu, F., & Gong, C. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.01.002 · Cited by 114
Young, J. E., Fong, L. K., Frankowski, H., Petsko, G. A., Small, S. A., & Goldstein, L. S. B. (2018) · Stem Cell Reports · doi:10.1016/j.stemcr.2018.01.031 · Cited by 110
Human tau pathology transmits glial tau aggregates in the absence of neuronal tau
Narasimhan, S., Changolkar, L. N., Riddle, D. M., Kats, A. S., Stieber, A., Weitzman, S. A., Zhang, B., Li, Z., Roberson, E. D., Trojanowski, J. Q., et al. (2019) · The Journal of Experimental Medicine · doi:10.1084/jem.20190783 · Cited by 109
Luna‐Muñoz, J., García‐Sierra, F., Falcón, V., Menéndez, I., Chávez-Macías, L., & Mena, R. (2005) · Journal of Alzheimer s Disease · doi:10.3233/jad-2005-8104 · Cited by 113
Biochemical and anatomical redistribution of tau protein in Alzheimer's disease.
Mukaetova-Ladinska, E., Harrington, C. R., Roth, M., & Wischik, C. M. (1993) · PubMed Central · Cited by 109
Fatty acids, lipid metabolism and Alzheimer pathology
Hooijmans, C. R., & Kiliaan, A. J. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.11.081 · Cited by 115
APOE is a major susceptibility gene for Alzheimer’s disease
Roses, A. D., & Saunders, A. M. (1994) · Current Opinion in Biotechnology · doi:10.1016/0958-1669(94)90091-4 · Cited by 108
Wang, X., Zeng, J., Yang, Y., Xiong, Y., Zhang, Z., Qiu, M., Xiong, Y., Sun, X., Tuo, Q., Liu, R., et al. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-140198 · Cited by 109
Serrano‐Pozo, A., Qian, J., Monsell, S. E., Frosch, M. P., Betensky, R. A., & Hyman, B. T. (2013) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0000000000000016 · Cited by 106
Self-citationThe effect of insomnia on development of Alzheimer’s disease
Sadeghmousavi, S., Eskian, M., Rahmani, F., & Rezaei, N. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01960-9 · Cited by 122
N-Acetylcholinesterase-Induced Apoptosis in Alzheimer's Disease
Toiber, D., Berson, A., Greenberg, D., Melamed‐Book, N., Diamant, S., & Soreq, H. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003108 · Cited by 107
Bussière, T., Friend, P. D., Sadeghi, N., Wicinski, B. A., Lin, G. I., Bouras, C., Giannakopoulos, P., Robakis, N. K. R. K., Morrison, J. H., Perl, D. P., et al. (2002) · Neuroscience · doi:10.1016/s0306-4522(02)00056-8 · Cited by 108
Song, X., Hu, J.-F., Chu, S., Zhang, Z., Xu, S., Yuan, Y., Han, N., Liu, Y., Niu, F., He, X., et al. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.03.051 · Cited by 107
Kensinger, E. A., Ullman, M. T., & Corkin, S. (2001) · Hippocampus · doi:10.1002/hipo.1049 · Cited by 107
Grimm, S., Höhn, A., Davies, K. J. A., & Grune, T. (2010) · Free Radical Research · doi:10.3109/10715762.2010.512040 · Cited by 112
Tau Positron Emission Tomography (PET) Imaging: Past, Present, and Future
Ariza, M., Kolb, H. C., Moechars, D., Rombouts, F. J. R., & Andrés, J. I. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm5017544 · Cited by 110
Brunden, K. R., Lee, V. M. ‐., Smith, A. B., Trojanowski, J. Q., & Ballatore, C. (2016) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.12.021 · Cited by 109
Mietelska‐Porowska, A., & Wojda, U. (2017) · Journal of Immunology Research · doi:10.1155/2017/4626540 · Cited by 111
Truncation of Tau selectively facilitates its pathological activities
Gu, J., Xu, W., Jin, N., Li, L., Zhou, Y., Chu, D., Gong, C., Iqbal, K., & Liu, F. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.012587 · Cited by 108
Regional cerebral glucose metabolism and postmortem pathology in Alzheimer’s disease
Mielke, R., Schröder, R., Fink, G. R., Kessler, J., Herholz, K., & Heiß, W.-D. (1996) · Acta Neuropathologica · doi:10.1007/s004010050410 · Cited by 107
Morphological substrates of cognitive decline in nonagenarians and centenarians: A new paradigm?
Imhof, A., Kövari, E., von Gunten, A., Gold, G., Rivara, C.-B., Herrmann, F. R., Hof, P. R., Bouras, C., & Giannakopoulos, P. (2007) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2007.01.025 · Cited by 106
Nava-Mesa, M. O., Jiménez‐Díaz, L., Yajeya, J., & Navarro‐López, J. D. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00167 · Cited by 106
Extracellular Vesicle Biology in Alzheimer’s Disease and Related Tauopathy
DeLeo, A. M., & Ikezu, T. (2017) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-017-9768-z · Cited by 109
Cinnamon, a promising prospect towards Alzheimer’s disease
Momtaz, S., Hassani, S., Khan, F., Ziaee, M., & Abdollahi, M. R. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.12.011 · Cited by 108
Role of Microglial Cells in Alzheimer’s Disease Tau Propagation
Španić, E., Horvat, L. L., Hof, P. R., & Šimić, G. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00271 · Cited by 112
Ranasinghe, K. G., Cha, J., Iaccarino, L., Hinkley, L. B. N., Beagle, A. J., Pham, J. Q., Jagust, W. J., Miller, B. L., Rankin, K. P., Rabinovici, G. D., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz4069 · Cited by 105
Imaging Amyloid-β Deposits In Vivo
Bacskai, B. J., Klunk, W. E., Mathis, C. A., & Hyman, B. T. (2002) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-200209000-00001 · Cited by 106
Self-citationIs DNA repair compromised in Alzheimer’s disease?
Davydov, V., Hansen, L. A., & Shackelford, D. A. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00229-4 · Cited by 106
Selden, N. R. W., Geula, C., Hersh, L. B., & Mesulam, M. M. (1994) · Neuroscience · doi:10.1016/0306-4522(94)90491-x · Cited by 107
Untangling Tau and Iron: Exploring the Interaction Between Iron and Tau in Neurodegeneration
Rao, S. S., & Adlard, P. A. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00276 · Cited by 108
Uzuegbunam, B. C., Librizzi, D., & Yousefi, B. H. (2020) · Molecules · doi:10.3390/molecules25040977 · Cited by 107
Effects of rosmarinic acid on nervous system disorders: an updated review
Rahbardar, M. G., & Hosseinzadeh, H. (2020) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-020-01935-w · Cited by 107
Distinct Pools of β-Amyloid in Alzheimer Disease–Affected Brain: A Clinicopathologic Study
Steinerman, J. R., Irizarry, M., Scarmeas, N., Raju, S., Brandt, J., Albert, M., Blacker, D., Hyman, B., & Stern, Y. (2008) · Archives of Neurology · doi:10.1001/archneur.65.7.906 · Cited by 104
Self-citationPalop, J. J., Mucke, L., & Roberson, E. D. (2010) · Methods in molecular biology · doi:10.1007/978-1-60761-744-0_17 · Cited by 104
Tau-Based Therapeutics for Alzheimer’s Disease: Active and Passive Immunotherapy
Panza, F., Solfrizzi, V., Seripa, D., Imbimbo, B. P., Lozupone, M., Santamato, A., Tortelli, R., Galizia, I., Prete, C., Daniele, A., et al. (2016) · Immunotherapy · doi:10.2217/imt-2016-0019 · Cited by 113
Mondal, A., Bose, D., Saha, P., Sarkar, S., Seth, R. K., Kimono, D. A., Albadrani, M. S., Nagarkatti, M., Nagarkatti, P. S., & Chatterjee, S. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01876-4 · Cited by 109
Mitochondrial Calcium Deregulation in the Mechanism of Beta-Amyloid and Tau Pathology
Esteras, N., & Abramov, A. Y. (2020) · Cells · doi:10.3390/cells9092135 · Cited by 106
O’Dell, R. S., Mecca, A. P., Chen, M.-K., Naganawa, M., Toyonaga, T., Lu, Y., Godek, T. A., Harris, J. E., Bartlett, H. H., Banks, E. R., et al. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00742-y · Cited by 107
The Role of Adenosine in Alzheimers Disease
Rahman, A. (2009) · Current Neuropharmacology · doi:10.2174/157015909789152119 · Cited by 106
Li, H., Liu, C.-C., Zheng, H., & Huang, T. Y. (2018) · Translational Neurodegeneration · doi:10.1186/s40035-018-0139-3 · Cited by 103
Leroy, K., Ando, K., Héraud, C., Yilmaz, Z., Authelet, M., Boeynaems, J.-M., Buée, L., De Decker, R., & Brion, J.-P. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-1276 · Cited by 103
Giannakopoulos, P., Hof, P. R., Mottier, S., Michel, J., & Bouras, C. (1994) · Acta Neuropathologica · doi:10.1007/bf00294172 · Cited by 104
Mechanisms of neuronal death in disease: defining the models and the players
Ribé, E. M., Serrano‐Saiz, E., Akpan, N., & Troy, C. M. (2008) · Biochemical Journal · doi:10.1042/bj20081118 · Cited by 107
Pathogenesis and Disease-modifying Therapy in Alzheimer's Disease: The Flat Line of Progress
Castellani, R. J., & Perry, G. L. (2012) · Archives of Medical Research · doi:10.1016/j.arcmed.2012.09.009 · Cited by 104
Vitali, P., Migliaccio, R., Agosta, F., Rosen, H., & Geschwind, M. D. (2008) · Seminars in Neurology · doi:10.1055/s-0028-1083695 · Cited by 105
Comparison of neuropathologic criteria for the diagnosis of Alzheimer's disease
Geddes, J. W., Tekirian, T. L., Soultanian, N. S., Ashford, J. W., Davis, D. G., & Markesbery, W. R. (1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00063-8 · Cited by 101
Characteristics of Tau and Its Ligands in PET Imaging
Harada, R., Okamura, N., Furumoto, S., Tago, T., Yanai, K., Arai, H., & Kudo, Y. (2016) · Biomolecules · doi:10.3390/biom6010007 · Cited by 104
Accelerated functional brain aging in pre-clinical familial Alzheimer’s disease
Gonneaud, J., Baria, A. T., Binette, A. P., Gordon, B. A., Chhatwal, J. P., Cruchaga, C., Jucker, M., Levin, J., Salloway, S., Farlow, M. R., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25492-9 · Cited by 109
Crowe, A., Huang, W., Ballatore, C., Johnson, R. L., Hogan, A. L., Huang, R., Wichterman, J., McCoy, J. G., Huryn, D. M., Auld, D. S., et al. (2009) · Biochemistry · doi:10.1021/bi9006435 · Cited by 104
Metadata
- Authors
- Arriagada, P. V., Growdon, J. H., Hedley-Whyte, E. T., & Hyman, B. T.
- Affiliations
- Harvard University (US)
- ORCID
- Hyman, Bradley T.
- Venue
- Neurology
- Published
- 1992-03
- Volume
- 42
- Issue
- 3
- Pages
- 631-631
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2053116497
- Cited by
- 2,668
- References
- 0
- Citations by year
- 2026: 54 · 2025: 89 · 2024: 81 · 2023: 101 · 2022: 89 · 2021: 141 · 2020: 135 · 2019: 131 · 2018: 96 · 2017: 112 · 2016: 132 · 2015: 101 · 2014: 106 · 2013: 93 · 2012: 97
- FWCI
- 28.79
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Neurology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (AG-08487, P50 AG05134, P50AG005134)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, neurofibrillary tangles, amyloid plaques, dementia severity, disease duration, neuropathology, entorhinal cortex, hippocampal formation, amygdala, regional vulnerability, cytoarchitecture
- MeSH terms
- Aged, Alzheimer Disease, Amygdala, Brain, Female, Hippocampus, Humans, Male, Middle Aged, Neurofibrillary Tangles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
